307 related articles for article (PubMed ID: 25617146)
1. Giant cell tumour of bone: new treatments in development.
López-Pousa A; Martín Broto J; Garrido T; Vázquez J
Clin Transl Oncol; 2015 Jun; 17(6):419-30. PubMed ID: 25617146
[TBL] [Abstract][Full Text] [Related]
2. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
4. Giant cell tumour of bone in the denosumab era.
van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
[TBL] [Abstract][Full Text] [Related]
5. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
7. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
8. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
9. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
10. An eggshell-like mineralized recurrent lesion in the popliteal region after treatment of giant cell tumor of the bone with denosumab.
Akaike K; Suehara Y; Takagi T; Kaneko K; Saito T
Skeletal Radiol; 2014 Dec; 43(12):1767-72. PubMed ID: 25052539
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
Knowles HJ; Athanasou NA
J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
[TBL] [Abstract][Full Text] [Related]
12. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
13. The current standing on the use of denosumab in giant cell tumour of the bone.
Singh VA; Puri A
J Orthop Surg (Hong Kong); 2020; 28(3):2309499020979750. PubMed ID: 33331233
[TBL] [Abstract][Full Text] [Related]
14. Giant cell tumour of bone.
Thomas DM; Skubitz KM
Curr Opin Oncol; 2009 Jul; 21(4):338-44. PubMed ID: 19444102
[TBL] [Abstract][Full Text] [Related]
15. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
16. A Translational Study of the Neoplastic Cells of Giant Cell Tumor of Bone Following Neoadjuvant Denosumab.
Mak IW; Evaniew N; Popovic S; Tozer R; Ghert M
J Bone Joint Surg Am; 2014 Aug; 96(15):e127. PubMed ID: 25100780
[TBL] [Abstract][Full Text] [Related]
17. Giant cell tumor of bone: current treatment options.
Skubitz KM
Curr Treat Options Oncol; 2014 Sep; 15(3):507-18. PubMed ID: 24788576
[TBL] [Abstract][Full Text] [Related]
18. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
19. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
[TBL] [Abstract][Full Text] [Related]
20. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
